Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has issued an announcement.
MindBio Therapeutics Corp. has announced a new financing initiative, including a private placement and debt settlements, to strengthen its financial position for future opportunities. The company completed a private placement for $174,783 and plans a non-brokered private placement to raise up to $110,000 for working capital and corporate purposes. Additionally, MindBio is working to settle $1,839,275 in outstanding debt through the issuance of shares, which will help streamline its financial obligations and enhance its market positioning.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing novel psychedelic-based medicines for mental health disorders. The company is pioneering the use of regulated, take-home use of psychedelic medicines with a focus on microdosing in clinical trials to provide treatments for conditions such as depression and anxiety. MindBio aims to improve global mental health outcomes through innovative, evidence-based treatment that is accessible and affordable.
Average Trading Volume: 122,725
Technical Sentiment Signal: Sell
For an in-depth examination of MBIO stock, go to TipRanks’ Stock Analysis page.